Effects of major ozonated autohemotherapy in the treatment of dry age related macular degeneration: a randomized controlled clinical study
Borrelli E, Diadori A, Zalaffi A, et al. International Journal of Ophthalmology, 2012.
- Study type
- Randomized controlled trial
- People studied
- 140 people
- Population
- Patients with dry age-related macular degeneration
- Published
- 2012, International Journal of Ophthalmology
- Identifiers
- PMID 23275905, DOI 10.3980/j.issn.2222-3959.2012.06.11
What the authors reported
In a randomized controlled trial of 140 patients, 27 sessions of major ozonated autohemotherapy over 12 months preserved visual acuity relative to multivitamin therapy and increased plasma antioxidant potential, with no loss of visual acuity in treated eyes versus substantial losses in controls.
What limits this result
PubMed does not tag this as a randomized controlled trial, so the design is inferred from the abstract's own description; a co-author is a leading proponent of ozone therapy, and masking of outcome assessors is not described.
Other ozone methods, such as major autohemotherapy, that clinics cite in support of EBO2. A result for one method does not transfer automatically to another. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
What Is EBO2 (EBOO) Therapy? Procedure, Evidence, Cost, and Safety
A neutral, sourced explainer of EBO2 (also called EBOO): how the procedure works, what the research shows, typical cost, and the FDA's position.